How Hungary’s richest man funneled millions into Orbán’s propaganda machine 
How Real Is the US Withdrawal from the Middle East? 
From Iran to China: An Emerging Trans-Central Asian Corridor The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA) said in a statement on Saturday.
The drug regulator did not reveal the number of transactions.
Advertisement
Outlicensing agreements typically involve a company granting another firm the exclusive rights to further develop, manufacture and commercialise a drug once it has entered human clinical trials, in return for upfront payments, milestone fees and royalties on future sales.
“Chinese biotech firms have shown substantial technological advancements over the past few years and some of their innovative research has piqued the interest of international pharmaceutical big names,” said Meng Tianying, a senior executive at Shanghai-based consultancy Domo Medical. “It has become a new bright spot of the Chinese economy in line with the government’s efforts to encourage innovation.”
Advertisement
Innovative drugs – novel medicines targeting unmet medical needs, including new chemical entities and advanced biologics – were expected to grow at an annualised pace of 20 per cent between 2026 and 2030 in mainland China, before slowing to 8.8 per cent from 2030 to 2040, according to Chen Chen, head of China healthcare research at UBS.
Don't Miss:
-
US wraps up military mission in Iraq, giving Baghdad room to strengthen China ties
-
As China and the EU begin crunch trade talks, optimism is in short supply
-
Data centre opposition is growing in Australia. Is there a middle ground?
-
Helper arrested for allegedly slapping 5-year-old boy after he refuses to eat
-
Workers, mostly Indian, building US consulate in Milan agree to record settlement